#VXRT

Lead report

Vaxart outlines Phase IIb COVID-19 top line data in first half of 2027 backed by BARDA funding (OTCMKTS:VXRT)

Vaxart (VXRT) Q2 2026 earnings call recap: Phase IIb oral COVID pill vaccine safety update, BARDA funding, cash runway, and 2027 catalysts—read now.